The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Editorial

Similar long-term outcome of dissimilar drug-eluting stents: is it time to change the assessment?

EuroIntervention 2021;16:e1468-e1469. DOI: 10.4244/EIJV16I18A266

1. Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, the Netherlands; 2. Department of Health Technology and Services Research, Faculty BMS, Technical Medical Centre, University of Twente, Enschede, the Netherlands


Long-term follow-up of randomised drug-eluting stent (DES) trials provides information that may be of great clinical value. While restenosis in DES generally occurs within the first two years, some safety and efficacy endpoints may only be seen at later stages. Most randomised trials that compared contemporary DES using Kaplan-Meier methods showed no significant difference in long-term outcome despite substantial between-DES differences in strut thickness, polymer type, stent design, and drug1,2,3. However, the inability to prove a difference is not the same as proof of no difference. In case of a negative trial result, in principle, there may be truly ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Optimising physiological endpoints of percutaneous coronary intervention